Here are the Form 4 insider transactions from BioLife Solutions Inc. (BLFS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BLFS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BLFS filings page.
BioLife Solutions Inc. Chief Financial Officer Troy Wichterman reported acquiring 76,204 and 62,300 shares under restricted-stock awards on October 6, 2026. The awards vested immediately before the merger, at approximately 200% of the number of shares granted, based on separate performance periods. He also reported 95,933 shares withheld for tax obligations at $38.61 per share and the disposition of 256,000 shares in the merger. At the merger's effective time, each outstanding BioLife common share converted into the right to receive $11.25 in cash and 0.1442 Repligen common shares, subject to the merger agreement.
BioLife Solutions Inc. (BLFS) director Joydeep Goswami reported a direct disposition to the issuer of 53,156 common shares on October 6, 2026, in connection with the consummation of its merger with Repligen Corporation. His reported direct holdings after the transaction were 0 shares.
BioLife Solutions director Rachel Ellingson disposed of 57,995 common shares on October 6, 2026, in connection with the consummation of the merger involving Repligen. Each outstanding BioLife share converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, subject to the merger agreement. Ellingson reported zero shares held directly after the transaction.
BioLife Solutions (BLFS) reports that director Amy DuRoss disposed of 26,857 common shares in connection with the merger completed October 6, 2026; her reported direct holdings after the transaction were 0 shares. Under the merger terms, each outstanding share of BioLife Solutions common stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, subject to the Merger Agreement.
BioLife Solutions director Catherine Coste disposed of 13,871 shares on October 6, 2026, in connection with the merger; her reported direct holdings afterward were 0 shares. Under the merger terms, each outstanding BioLife common share converted into the right to receive $11.25 in cash and 0.1442 Repligen common shares, subject to the merger agreement.
BioLife Solutions Inc. Chief Executive Officer and director Roderick de Greef reported two restricted-stock acquisitions and merger-related dispositions on October 6, 2026. The acquisitions were 225,670 shares and 237,460 shares; both awards vested immediately before the merger at approximately 200% of the shares granted, based on total shareholder return relative to certain peers over separate measurement periods ending October 2, 2026.
De Greef disposed of 826,454 shares in connection with the merger. Each outstanding common share converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, subject to the merger agreement. Separately, 364,872 shares were withheld for tax obligations in connection with vesting, at $38.61 per share.
BioLife Solutions (BLFS) director Anthony Hunt reported a disposition of 15,046 common shares on October 6, 2026, in connection with consummation of the First Merger under an agreement involving Repligen Corporation. At the effective time, each outstanding BioLife share converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, subject to the merger agreement. Hunt reported zero direct shares following the transaction. No Rule 10b5-1 plan is reported.
BioLife Solutions (BLFS) director Timothy L. Moore returned 44,943 shares to the issuer on October 6, 2026, in connection with the consummation of its merger with Repligen Corporation. Under the merger terms, each outstanding BioLife common share converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, subject to the Merger Agreement. Moore's reported direct holdings after the disposition were zero shares.
BioLife Solutions EVP & Chief Scientific Officer Aby J. Mathew reported acquiring 45,838 and 40,192 shares of restricted stock on October 6, 2026. The awards vested immediately before the merger’s effective time at approximately 200% of the number of shares granted, based on performance comparisons described in the award terms.
Mathew also reported that 70,000 shares were withheld to cover tax obligations, at a reported price of $38.61 per share, and a disposition of 404,608 shares in connection with the merger’s consummation. At the effective time, each outstanding BioLife common share converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, subject to the merger agreement.
BioLife Solutions Inc. Chief Marketing Officer Todd Berard reported acquiring 38,198 and 40,192 shares of restricted stock on October 6, 2026; both awards vested immediately before the merger’s effective time. Each award vested at approximately 200% of the number of shares granted, based on BioLife’s total shareholder return compared with certain peers over periods beginning January 1, 2025 and January 1, 2026, respectively, through October 2, 2026. Berard also reported that 46,170 shares were withheld to cover tax withholding obligations, with a reported price of $38.61 per share, and that 194,786 shares were disposed of in connection with the merger. Each outstanding BioLife common share converted into a right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, subject to the merger agreement’s terms and conditions.
BioLife Solutions Chief Technology Officer Sean Werner reported acquiring 45,838 shares and 48,232 shares under restricted-stock awards on October 6, 2026. Both awards vested immediately before the merger effective time at approximately 200% of the number of shares granted, based on BioLife’s total shareholder return compared with certain peers over separate performance periods. Werner also reported 71,226 shares withheld for tax obligations at a reported price of $38.61 per share, and the disposition of 69,979 shares in connection with the consummation of the merger with Repligen Corporation. Under the merger terms, each BioLife common share converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, subject to the merger agreement.
BIOLIFE SOLUTIONS INC (BLFS) reported that Chief Marketing Officer Todd Berard had 470 shares of common stock withheld on September 18, 2026 to satisfy tax withholding obligations arising from the release of restricted stock units. After this tax-withholding disposition, he holds 161,823 shares of common stock directly. No transactions were reported under a Rule 10b5-1 trading plan.
BIOLIFE SOLUTIONS INC (BLFS) executive Mathew Aby J., EVP & Chief Scientific Officer, had 564 shares of common stock withheld on September 18, 2026 to satisfy tax withholding obligations arising from the release of restricted stock units, at a reference price of $36.69 per share. After this tax-withholding disposition, he holds 387,269 shares of BIOLIFE SOLUTIONS INC common stock directly. No Rule 10b5-1 trading plan is reported for this transaction.
BIOLIFE SOLUTIONS INC (BLFS) reported that Chief Technology Officer Sean Werner had 421 shares of common stock withheld on September 18, 2026 to satisfy tax withholding obligations arising from the release of restricted stock units, at a value of $36.69 per share. After this tax-withholding disposition, he holds 47,135 shares of the company’s common stock directly, and no Rule 10b5-1 trading plan is reported for this transaction.
BIOLIFE SOLUTIONS INC (BLFS) director and President and CEO Roderick De Greef reported a Form 4 transaction involving company common stock. On September 18, 2026, 2,775 shares were withheld and disposed of to satisfy his tax withholding obligations arising from the release of restricted stock units, at a price of $36.69 per share. Following this tax-withholding transaction, he held 728,196 shares of common stock directly. No transactions were reported as made under a Rule 10b5-1 trading plan.
BIOLIFE SOLUTIONS INC (BLFS) reported that its Chief Financial Officer, Troy Wichterman, had 937 shares of common stock withheld on September 18, 2026 to satisfy tax withholding obligations arising from the release of restricted stock units. After this tax-withholding disposition, he directly holds 211,286 shares of BLFS common stock.
BIOLIFE SOLUTIONS INC (BLFS) reported that Chief Marketing Officer Todd Berard had 356 shares of common stock withheld on September 8, 2026 to satisfy his tax withholding obligations arising from the release of restricted stock units. The shares were withheld by the company rather than sold in the market, and Berard continues to hold 162,293 shares of BIOLIFE common stock directly after this tax-withholding disposition. No Rule 10b5-1 trading plan is reported for this transaction.
BIOLIFE SOLUTIONS INC (BLFS) reported that executive vice president and chief scientific officer Mathew Aby J. had 627 shares of common stock withheld on September 8, 2026 to satisfy tax withholding obligations arising from the release of restricted stock units. The shares were valued at $35.38 per share, and he now directly holds 387,833 shares of common stock. This was a tax-withholding disposition rather than an open-market sale, and no Rule 10b5-1 trading plan is reported.
BIOLIFE SOLUTIONS INC (BLFS) reported that Chief Financial Officer Troy Wichterman had 1,026 shares of common stock withheld on September 8, 2026 to satisfy his tax withholding obligations arising from the release of restricted stock units. The shares were valued at $35.38 per share, and he now holds 212,223 shares directly. The transaction was a tax-withholding disposition, not an open-market sale, and no Rule 10b5-1 trading plan is reported.
BioLife Solutions Inc. Chief Technology Officer Sean Werner reported a tax-withholding disposition of 275 shares of Common Stock on July 17, 2026 at $29.15 per share. These shares were withheld by the company to satisfy Werner's tax obligations arising from the release of restricted stock units. After this withholding, Werner directly holds 47,556 shares of BioLife Solutions Common Stock.
BioLife Solutions’ Chief Financial Officer Troy Wichterman reported a Form 4 transaction involving 844 shares of common stock with a value of $27.79 per share. According to the disclosure, these shares were withheld by the company to satisfy tax withholding obligations arising from the release of restricted stock units, rather than sold in the open market. Following this tax-withholding disposition, Wichterman directly holds 213,249 shares of common stock.
BioLife Solutions executive Mathew Aby J., EVP & Chief Scientific Officer, reported a tax-withholding disposition of 516 shares of common stock on July 7, 2026. The shares were withheld by the company to satisfy tax obligations upon the release of restricted stock units, and Aby now holds 388,460 shares directly.
BioLife Solutions Inc Chief Marketing Officer Todd Berard reported a tax-withholding disposition of 293 shares of Common Stock on 2026-07-07. The issuer withheld these shares to satisfy Berard’s tax obligations upon the release of restricted stock units at $27.79 per share, leaving him with 162,649 shares owned directly.
BioLife Solutions Chief Marketing Officer Todd Berard had 470 shares of common stock withheld by the company on the RSU vesting date to cover tax obligations. This was a tax-withholding disposition, not an open-market sale. After this withholding, he directly holds 162,942 shares of BioLife Solutions common stock.
BIOLIFE SOLUTIONS INC Chief Technology Officer Sean Werner reported a small share disposition related to taxes, not an open-market trade. On the transaction date, 420 shares of Common Stock were withheld by the company at a price of $26.04 per share to cover tax withholding obligations that arose when restricted stock units were released. After this tax-withholding event, Werner held a remaining direct position of 47,831 Common Stock shares.
BioLife Solutions President and CEO Roderick De Greef reported a routine tax-related share withholding. The company withheld 2,775 shares of common stock to satisfy his tax obligations when restricted stock units were released. After this non-market transaction, he directly holds 730,971 shares of BioLife Solutions common stock.
BioLife Solutions Chief Financial Officer Troy Wichterman reported a routine tax-related share disposition. On the release of restricted stock units, the company withheld 937 shares of Common Stock to cover his tax obligations at a value of $26.04 per share. After this withholding, Wichterman directly holds 214,093 shares of BioLife Solutions common stock, indicating that the event reflects compensation-related tax settlement rather than an open-market sale.
BIOLIFE SOLUTIONS INC executive Mathew Aby J., EVP & Chief Scientific Officer, reported a small share disposition tied to taxes rather than a market trade. On the release of restricted stock units, 564 shares of common stock were withheld by the company at $26.04 per share to satisfy his tax obligations. After this automatic tax-withholding event, he directly holds 388,976 shares of BIOLIFE SOLUTIONS INC common stock.
BioLife Solutions Chief Financial Officer Troy Wichterman reported a routine tax-related share disposition. On the reported date, 1,026 shares of common stock were withheld by the company to satisfy his tax withholding obligations arising from the release of restricted stock units, rather than being sold in the open market.
After this tax-withholding event, Wichterman directly holds 215,030 shares of BioLife Solutions common stock, indicating he retains a substantial equity position. This filing reflects a compensation-related, non-discretionary transaction tied to vesting, not an active decision to buy or sell shares on the market.
BioLife Solutions Inc. Chief Marketing Officer Todd Berard reported a routine tax-related share disposition. On the release of restricted stock units, 356 shares of Common Stock were withheld by the company to cover his tax withholding obligations. Following this, he directly holds 163,412 shares, so his overall stake remains largely unchanged and the transaction does not represent an open-market sale.
BIOLIFE SOLUTIONS INC executive Mathew Aby J., EVP & Chief Scientific Officer, reported a small, routine share disposition related to taxes. On June 8, 2026, 627 shares of common stock were withheld at $26.10 per share to satisfy tax withholding obligations that arose when restricted stock units were released. After this tax-withholding event, he directly held 389,540 shares of common stock.
BioLife Solutions Inc. reported insider activity by Casdin-affiliated entities. Casdin Partners Master Fund, L.P. completed open-market sales totaling 1,200,000 shares of common stock over three days. The fund sold 300,000 shares at $22.65 on May 19, 2026, 250,000 shares at $23.70 on May 20, and 650,000 shares at $23.70 on May 21. After these sales, the Master Fund continued to hold 4,757,165 shares indirectly. According to the footnote, these securities are owned directly by the Master Fund and may be deemed indirectly beneficially owned by Casdin Capital, LLC, Casdin Partners GP, LLC, and Eli Casdin.
BioLife Solutions EVP and Chief Scientific Officer Mathew Aby J. reported a small share disposition related to taxes, not an open-market trade. On the release of restricted stock units, 515 shares of common stock were withheld by the company at $19.27 per share to satisfy his tax obligations. After this tax-withholding event, he directly holds 390,167 shares of BioLife Solutions common stock.
BIOLIFE SOLUTIONS INC Chief Marketing Officer Todd Berard reported a routine share disposition related to taxes. On the transaction date, 293 shares of common stock were withheld by the company to satisfy his tax withholding obligations that arose when restricted stock units were released. This was not an open-market sale. After this tax-withholding event, Berard directly held 163,768 shares of BIOLIFE SOLUTIONS INC common stock.
BioLife Solutions Inc. Chief Financial Officer Troy Wichterman had 844 shares of common stock withheld on April 8, 2026 to cover tax obligations from the release of restricted stock units. The shares were valued at $19.27 each, and he now directly holds 216,056 shares.
BioLife Solutions Inc. executive Karen A. Foster sold 2,577 shares of common stock in an open-market transaction. The sale occurred at a weighted average price of $19.17 per share and was executed under a pre-arranged Rule 10b5-1(c) trading plan adopted effective December 4, 2025.
Following this transaction on March 23, 2026, Foster directly held 108,758 shares of BioLife Solutions common stock. The shares were sold in multiple trades at prices ranging from $18.99 to $19.35, and detailed breakdowns are available upon request as noted in the filing.
BioLife Solutions Inc. President and CEO Roderick De Greef had 11,101 shares of Common Stock withheld to cover taxes on restricted stock units that vested. These shares were delivered back to the company as a tax-withholding disposition, not sold on the open market. Following this transaction, he directly holds 733,746 shares of BioLife Solutions common stock.
BioLife Solutions Inc. reported an insider tax-withholding transaction by Chief Marketing Officer Todd Berard. On the release of restricted stock units, 1,879 shares of common stock were withheld by the company to cover his tax obligations. After this non-market disposition, Berard directly holds 164,061 shares of BioLife Solutions common stock.
BIOLIFE SOLUTIONS INC Chief Technology Officer Sean Werner reported a routine tax-related share disposition. On the release of restricted stock units, the company withheld 1,681 shares of common stock at $19.12 per share to cover his tax obligations. After this withholding, Werner directly holds 48,251 shares of BIOLIFE SOLUTIONS common stock. This was not an open-market trade but an automatic share withholding mechanism tied to equity compensation.
BioLife Solutions Inc.'s Chief Financial Officer Troy Wichterman reported a routine tax-related share withholding tied to restricted stock vesting. On this Form 4, 3,749 shares of Common Stock were withheld at $19.12 per share to satisfy tax obligations that arose when restricted stock units were released.
These shares were not sold in the open market; they were retained by the company to cover taxes. After this transaction, Wichterman holds 216,900 shares of BioLife Solutions common stock directly, indicating he retains a substantial equity position following the RSU vesting event.
BioLife Solutions Inc. Chief Human Resources Officer Sarah Aebersold reported a routine tax-related share disposition. On the release of restricted stock units, the company withheld 931 shares of common stock to cover her tax obligations at $19.12 per share. After this withholding, she directly owns 92,429 shares. This was not an open-market sale but a standard mechanism tied to equity compensation vesting.
BioLife Solutions executive Karen A. Foster had shares withheld to cover taxes on equity compensation. On the release of restricted stock units, the company withheld 1,907 shares of Common Stock at a value of $19.12 per share to satisfy her tax obligations. After this tax-withholding disposition, she holds 111,335 shares of BioLife Solutions Common Stock directly.
BioLife Solutions EVP & Chief Scientific Officer Mathew Aby J. reported a routine tax-related share disposition. On the release of restricted stock units, 2,255 shares of common stock were withheld by the company at $19.12 per share to cover his tax obligations. After this withholding, he continues to directly own 390,682 shares of BioLife Solutions common stock, indicating that only a small portion of his overall holdings was affected and that this was not an open-market sale.
BioLife Solutions Chief Quality and Operations officer Karen A. Foster reported open-market sales of a total of 97,423 shares of common stock in two transactions, at weighted average prices of $20.15 and $20.00 per share across multiple trades. After these sales, she directly owns 113,242 shares.
BioLife Solutions Inc. reported that Chief Technology Officer Sean Werner executed an open-market sale of 111 shares of common stock on March 3, 2026 at $20.74 per share. The transaction was made under a pre-arranged Rule 10b5-1(c) trading plan.
According to the filing, the trading plan, effective February 24, 2022, was established to satisfy tax withholding obligations arising from the vesting of restricted stock. After this sale, Werner directly holds 49,932 shares of BioLife Solutions common stock.
BioLife Solutions Inc. executive Karen A. Foster, Chief Quality and Operations, sold 418 shares of common stock in an open-market transaction at $20.74 per share. After this sale, she directly owned 210,665 shares. The sale was executed under a pre-established Rule 10b5-1(c) trading plan adopted to cover tax withholding tied to the vesting of restricted stock.
BioLife Solutions executive Mathew Aby J., EVP & Chief Scientific Officer, sold 529 shares of common stock at $20.74 per share in an open‑market transaction. The sale was made under a Rule 10b5-1(c) trading plan adopted effective 02-24-2022 to cover tax withholding from vested restricted stock. After this sale, he directly held 392,937 common shares.
BioLife Solutions Inc. Chief Financial Officer Troy Wichterman reported an open-market sale of 588 shares of common stock at $20.74 per share. The transaction occurred on March 3, 2026 and was executed under a pre-established Rule 10b5-1(c) trading plan.
The footnote explains the sale was made to satisfy tax withholding obligations related to the vesting of restricted stock. After this sale, Wichterman continues to hold 220,649 shares of BioLife Solutions common stock directly.
BioLife Solutions Inc. executive files small preplanned stock sale. Chief Human Resources Officer Sarah Aebersold sold 219 shares of common stock on March 3, 2026 in an open-market transaction at $20.74 per share. The sale was made under a Rule 10b5-1(c) trading plan adopted effective February 24, 2022 to satisfy tax withholding obligations from vested restricted stock. After this transaction, she directly holds 93,360 shares of BioLife Solutions common stock.
BioLife Solutions Inc. Chief Marketing Officer Todd Berard reported an open-market sale of 353 shares of common stock at $20.74 per share on March 3, 2026. After this transaction, he directly held 165,940 shares of BioLife Solutions common stock.
According to the footnote, this sale was executed under a pre-established Rule 10b5-1(c) trading plan, adopted effective February 24, 2022. The plan was designed to satisfy tax withholding obligations related to the vesting of restricted stock, indicating the sale was part of a planned, tax-driven process rather than a discretionary trade.